Systemic lupus erythematosus, atherosclerosis, and autoantibodies

Annals of the New York Academy of Sciences

Volumn 1051, Issue , 2005, Pages 351-361

  Zampieri, Sandra ^a   Iaccarino, Luca ^a   Ghirardello, Anna ^a   Tarricone, Elena ^a   Arienti, Silvia ^a   Sarzi Puttini, Piercarlo ^b   Gambari, Pierfranca ^a   Doria, Andrea ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Autoantibodies; Cardiovascular disease; Heat shock proteins; Oxidized low density lipoprotein; Phospholipid proteins; Risk factors; Systemic lupus erythematosus; 2 glycoprotein I

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 60 ANTIBODY; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 65 ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONFERENCE PAPER; HUMAN; INFLAMMATION; MORBIDITY; MORTALITY; PATHOGENESIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 25444437453     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1361.077     Document Type: Conference Paper

References (64)

1. WICK, G., G. SCHETT, A. AMBERGER, et al. 1995. Is atherosclerosis an immunological mediated disease? Immunol. Today 16: 27-33.
2. WARD, M.M. 1999. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42: 338-346.
3. GLADMAN, D.D. & M.B. UROWITZ. 1987. Morbidity in systemic lupus erythematosus. J. Rheumatol. 14: 223-226.
4. BULKLEY, B.H. & W.C. ROBERTS. 1975. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy: a study of 36 necroscopy cases. Am. J. Med. 53: 243-264.
5. UROWITZ, M.B., A.A. BOOKMAN, B.E. KOEHLER, et al. 1976. The bimodal mortality pattern of SLE. Am. J. Med. 60: 221-225.
6. PETRI, M., S. PEREZ-GUTTHANN, D. SPENCE, et al. 1992. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am. J. Med. 93: 513-519.
7. ESDAILE, J.M., M. ABRAHAMOWICZ, T. GRODZICKY, et al. 2001. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44: 2231-2237.
8. MANZI, S., F. SELZER, K. SUTTON-TYRRELI, et al. 1999. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 42: 51-60.
9. GEORGE, J., D. HARATS, B. GILBURD, et al. 1999. Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 8: 220-226.
10. DORIA, A., Y. SHOENFELD, R. WU, et al. 2003. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 62: 1071-1077.
11. ROSS, R. 1999. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340: 115-126.
12. SHERER, Y. & Y. SHOENFELD. 2002. Is atherosclerosis a cellular or humoral mediated autoimmune disease? Ann. Rheum. Dis. 61: 97-99.
13. MACH, F., U. SCHONBECK, G.K. SUKHOVA, et al. 1998. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 394: 200-203.
14. EMESON, E.E., M.L. SHEN, C.G. BELL, et al. 1996. Inhibition of atherosclerosis in CD4 T-cell-depleted and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am. J. Pathol. 149: 675-685.
15. HANSSON, G.K., P. LIBBY, U. SCHONBECK & Z.Q. YAN. 2002. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91: 281-291.
16. KOBAYASHI, K., M. KISHI, T. ATSUMI, et al. 2003. Circulating oxidized LDL forms immune complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J. Lipid Res. 44: 716-726.
17. SHOENFELD, Y., Y. SHERER, J. GEORGE & D. HARATS. 2000. Autoantibodies associated with atherosclerosis. Ann. Med. 32: 37-40.
18. PALINSKI, W., E. MILLER & J.L. WITZTUM. 1995. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Natl. Acad. Sci. USA 92: 821-825.
19. GEORGE, J., A. AFEK, B. GILBURD, et al. 1998. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98: 1108-1115.
20. AFEK, A., J. GEORGE, B. GILBURD, et al. 2000. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J. Autoimmun. 14: 115-121.
21. NICOLO, D. & M. MONESTIER. 2004. Antiphospholipid antibodies and atherosclerosis. Clin. Immunol. 112: 183-189.
22. SHOENFELD, Y., R. WU, D.L. DEARING & E. MATSUURA. 2004. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 110: 2552-2558.
23. FROSTEGARD, J., A. HAEGERSTRAND, M. GIDLUND & J. NILSSON. 1991. Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 90: 119-126.
24. STEMME, S., B. FABER, J. HOLM, et al. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 92: 3893-3897.
25. FROSTEGARD, J., Y.H. HUANG, J. RONNELID & L. ELINDER-SCHAFER. 1997. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler. Thromb. Vasc. Biol. 17: 963-968.
26. BROWN, M.S. & J.L. GOLDSTEIN. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science 232: 34-47.
27. LOPES-VIRELLA, M.F., N. BINZAFAR, S. RACKLEY, et al. 1997. The uptake of LDL-IC by human macrophages: predominant involvement of the FcgRI receptor. Atherosclerosis 135: 161-170.
28. LEHTIMAKI, T., S. LEHTINEN, T. SOLAKIVI, et al. 1999. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 19: 23-27.
29. MAGGI, E., R. CHIESA, G. MELISSANO, et al. 1994. LDL oxidation in patients with severe carotid atherosclerosis. A study of in vitro and in vivo oxidation markers. Arterioscler. Thromb. 14: 1892-1899.
30. SALONEN, J.T., S. YLA-HERTTUALA, R. YAMAMOTO, et al. 1992. Autoantibodies against oxidised LDL and progression of carotid atherosclerosis. Lancet 339: 883-887.
31. MERAVIGLIA, M.V., E. MAGGI, G. BELLOMO, et al. 2002. Autoantibodies against oxidatively modified lipoproteins and progression of carotid restenosis after carotid endarterectomy. Stroke 33: 1139-1141.
32. GEORGE, J., D. HARATS, E. BAKSHI, et al. 1999. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol. Lett. 68: 263-266.
33. GEORGE, J., A. AFEK, B. GILBURD, et al. 1998. Hyperimmunization of apo-E mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138: 147-152.
34. AMELI, S., A. HULTGARDH-NILSSON, J. REGNSTROM, et al. 1996. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Atheroscler. Thromb. Vasc. Biol. 16: 1074-1079.
35. SHAW, P.X., S. HORKKO, S. TSIMIKAS, et al. 2001. Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo. Atheroscler. Thromb. Vasc. Biol. 21: 333-339.
36. HAYEM, G., P. NICAISE-ROLAND, E. PALAZZO, et al. 2001. Anti-oxidized low-density-lipoprotein (OxLDL) antibodies in systemic lupus erythematosus with and without antiphospholipid syndrome. Lupus 10: 346-351.
37. SVENUNGSSON, E., K. JENSEN-URSTAD, M. HEIMBÜRGER, et al. 2001. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104: 1887-1893.
38. FROSTEGARD, J. 2002. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun. Rev. 1: 233-237.
39. SCHWARZENBACHER, R., K. ZETH, K. DIEDERICHS, et al. 1999. Crystal structure of human beta 2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J. 18: 6228-6239.
40. 2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum. 46: 2686-2694.
41. HASUNUMA, Y., E. MATSUURA, Z. MAKITA, et al. 1997. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. 107: 569-573.
42. GEORGE, J., D. HARATS, B. GILBURD, et al. 1999. Immunolocalization of b2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99: 2227-2230.
43. AFEK, A., J. GEORGE, Y. SHOENFELD, et al. 1999. Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice. Pathobiology 67: 19-25.
44. GEORGE, J., D. HARATS, B. GILBURD, et al. 2000. Adoptive transfer of beta-2-glycoprotein-I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102: 1822-1827.
45. VAARALA, O., M. MANTTARI, V. MANNINEN, et al. 1995. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91: 23-27.
46. SHERER, Y., J. SHEMESH, A. TENENBAUM, et al. 2000. Coronary calcium and anti-cardiolipin antibody are elevated in patients with typical chest pain. Am. J. Cardiol. 86: 1306-1311.
47. SHERER, Y., A. TENENBAUM, M. BLANK, et al. 2001. Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, β-2-glycoprotein-I, and oxidized-LDL antibodies. Cardiology 95: 20-24.
48. AMES, P.R., A. MARGARITA, J. DELGADO ALVES, et al. 2002. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11: 208-214.
49. MEDINA, G., D. CASAOS, L.J. JARA, et al. 2003. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann. Rheum. Dis. 42: 607-610.
50. VLACHOYIANNOPOULOS, P.G., P.G. KANELLOPOULOS, J.P. IOANNIDIS, et al. 2003. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 42: 645-651.
51. GHIRARDELLO A., A. DORIA, A. RUFFATTI, et al. 1994. Antiphospholipid antibodies (aPL) in systemic lupus erythematosus: are they specific tools for the diagnosis of aPL syndrome? Ann. Rheum. Dis. 54: 140-142.
52. SELZER, F., K. SUTTON-TYRRELL & S.G. FITZGERALD, et al. 2004. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum. 50: 151-159.
53. PHADKE, K.V., R.A. PHILLIPS, D.T. CLARKE, et al. 1993. Anticardiolipin antibodies in ischemic heart disease: marker or myth? Br. Heart J. 69: 391-394.
54. ROMAN, M.J., B.A. SHAKER, A. DAVIS, et al. 2003. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2399-2406.
55. XU, Q. & G. WICK. 1996. The role of heat shock proteins in protection and pathophysiology of the arterial wall. Mol. Med. Today 2: 372-379.
56. YOUNG, R.A. & T.J. ELLIOTT. 1989 Stress proteins, infection and immune surveillance. Cell 59: 5-8.
57. SORELLE R. 2002. Blood containing high levels of antibodies to heat shock protein 65 (hsp65) were found to be at increased risk of subsequent cardiovascular events. Circulation 106: 9052-9058.
58. XU, Q., S. KIECHL, M. MAYR, et al. 1999. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 100: 1169-1174.
59. XU, Q., J. WILLEIT, M. MAROSI, et al. 1993. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 341: 255-259.
60. XU, Q., H. DIETRICH, H.J. STEINER, et al. 1992. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. 12: 789-799.
61. GEORGE, J., Y. SHOENFELD, A. AFEK, et al. 1999. Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler. Thromb. Vasc. Biol. 19: 505-510.
62. GRUBER, R., S. LEDERER, U. BECHTEL, et al. 1996. Increased antibody titers against mycobacterial heat-shock protein 65 in patients with vasculitis and arteriosclerosis. Int. Arch. Allergy Immunol. 110: 95-98.
63. HORVATH, L., L. CZIRJAK, B. FEKETE, et al. 2001. Levels of antibodies against CIq and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol. Lett. 75: 103-109.
64. WU, R. 2001. Autoantibodies against oxidized palmitoyl arachidonoyl phosphocholine in atherosclerosis. In Atherosclerosis and autoimmunity. Y. Shoenfeld, D. Harats & G. Wick, Eds.: 151-159. Elsevier. Amsterdam.